Cullinan Therapeutics, Inc. CGEM

US Biotechnology

$11.29 ▼ -3.75% ($-0.44)

Open $11.64

Prev Close $11.73

Day Range $10.95 – $12.05

52W Range $6.73 – $23.19

Market Cap $754.88M

Beta 0.05

EPS (TTM) $-3.41

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2021-01-08
Shares Out.	64,350,000
Website	cullinantherapeutics.com/ ↗
Phone	13026587581
Employees	109
Revenue	$0
Gross Profit	$0
Net Income	-$53.7M
Free Cash Flow	-$159.3M
Total Assets	$363.8M
Total Liabilities	$42.0M
Equity	$321.8M

About Cullinan Therapeutics, Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Cullinan Therapeutics, Inc. is a publicly traded company under the ticker symbol CGEM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.